Cite
HARVARD Citation
Watanabe, K. et al. (2020). Dual EGFR and ABL Tyrosine Kinase Inhibitor Treatment in a Patient with Concomitant EGFR-Mutated Lung Adenocarcinoma and BCR-ABL1-Positive CML. Case reports in oncological medicine. p. . [Online].